Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1, Supplement 1 , Pages S67-S76 , January 2008

Differentiating Alzheimer’s disease from dementia with Lewy bodies and Parkinson’s disease with (+)-[11C]dihydrotetrabenazine positron emission tomography

  • Robert A. Koeppe

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, The University of Michigan, Ann Arbor, MI, USA
    • Corresponding Author InformationCorresponding author. Tel.: 734-763-9247; Fax: 734-764-2088.
    • ,
  • Sid Gilman

      Affiliations

    • Department of Neurology, The University of Michigan, Ann Arbor, MI, USA
    • ,
  • Larry Junck

      Affiliations

    • Department of Neurology, The University of Michigan, Ann Arbor, MI, USA
    • ,
  • Kris Wernette

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, The University of Michigan, Ann Arbor, MI, USA
    • Department of Neurology, The University of Michigan, Ann Arbor, MI, USA
    • ,
  • Kirk A. Frey

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, The University of Michigan, Ann Arbor, MI, USA
    • Department of Neurology, The University of Michigan, Ann Arbor, MI, USA

References 

  1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–1342
  2. Kukull WA, Bowen JD. Dementia epidemiology. Med Clin North Am. 2002;86:573–590
  3. Guttman M, Slaughter PM, Theriault M-E, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Dis. 2003;18:313–319
  4. Strickland D, Bertoni JM. Parkinson’s prevalence estimated by a state registry. Mov Dis. 2004;19:318–323
  5. Ince PG, McKeith IG. Dementia with Lewy bodies. In:  Dickson DW, et al. editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: International Society of Neuropathology Press; 2003;p. 188–199
  6. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113–1124
  7. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Neurology. 1999;53:902–905
  8. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–1872
  9. Martí MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord. 2003;18(Suppl 6):S21–S27
  10. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson’s and Alzheimer’s diseases matched for dementia severity. J Nucl Med. 1997;38:797–802
  11. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer’s disease. Ann Neurol. 2004;55:774–780
  12. Bohnen NI, Albin RL, Koeppe RA, Wernette K, Kilbourn MR, Minoshima S, et al. Positron emission tomography of striatal monoaminergic vesicular binding in normal aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198–1212
  13. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936–944
  14. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol. 1999;56:33–39
  15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944
  16. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementia. Ann Neurol. 1980;7:486–488
  17. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatric Res. 1975;12:189–198
  18. Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995;278:249–252
  19. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab. 1997;17:919–931
  20. Minoshima S, Koeppe RA, Mintun MA, Berger KL, Taylor SF, Frey KA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med. 1993;34:322–329
  21. Vander Borght TM, Kilbourn MR, Koeppe RA, DaSilva JN, Carey JE, Kuhl DE, et al. In vivo imaging of the brain vesicular monoamine transporter. J Nucl Med. 1995;36:2252–2260
  22. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab. 1999;19:1376–1384
  23. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 1984;15:217–227
  24. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153–158
  25. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–1539
  26. Minoshima S, Koeppe RA, Fessler JA, Mintun MA, Berger KL, Taylor SF, et al. Integrated and automated data analysis method for neuronal activation studies using O15 water PET. In:  Uemura K,  Lassen NA,  Jones T,  Kanno I editor. Quantification of brain function: tracer kinetics and image analysis in brain PET (International Congress Series 1030). Tokyo: Excerpta Medica; 1993;p. 409–418
  27. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35:1528–1537
  28. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. New York: Thieme; 1988;
  29. Frey KA, Minoshima S, Koeppe RA, Kilbourn MR, Berger KL, Kuhl DE. Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. J Cereb Blood Flow Metab. 1996;16:409–417
  30. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–134
  31. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64:1404–1410
  32. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson’s disease. J Neurol Sci. 2006;248:255–258
  33. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Advances in Neurology. 2001;86:237–247

PII: S1552-5260(07)00657-7

doi: 10.1016/j.jalz.2007.11.016

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 4, Issue 1, Supplement 1 , Pages S67-S76 , January 2008

Article Tools

* Image Usage & Resolution